ERBB2 and neoplasm: In recent years, we have witnessed how a better understanding of tumor biology and resistance mechanisms has promoted the development of new targeted drugs more specific and potent, as HER2-positive breast cancer is one example of the most successful subtypes to benefit from these strategies.